AU6839196A - Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof - Google Patents

Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof

Info

Publication number
AU6839196A
AU6839196A AU68391/96A AU6839196A AU6839196A AU 6839196 A AU6839196 A AU 6839196A AU 68391/96 A AU68391/96 A AU 68391/96A AU 6839196 A AU6839196 A AU 6839196A AU 6839196 A AU6839196 A AU 6839196A
Authority
AU
Australia
Prior art keywords
cytokine
methods
endogenous production
production enhancer
hemopoietic factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU68391/96A
Inventor
Mark Borisovich Balazovsky
Leonid Andreevich Kozhemyakin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU6839196A publication Critical patent/AU6839196A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU68391/96A 1995-12-14 1996-08-08 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof Abandoned AU6839196A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RO95120403 1995-12-14
RU95120403/14A RU2089179C1 (en) 1995-12-14 1995-12-14 Stimulator of cytokin and hemopoietic factors production and a method of its using
PCT/RU1996/000226 WO1997021443A1 (en) 1995-12-14 1996-08-08 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof

Publications (1)

Publication Number Publication Date
AU6839196A true AU6839196A (en) 1997-07-03

Family

ID=20174317

Family Applications (1)

Application Number Title Priority Date Filing Date
AU68391/96A Abandoned AU6839196A (en) 1995-12-14 1996-08-08 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof

Country Status (8)

Country Link
US (1) US6165979A (en)
CN (1) CN1161149C (en)
AU (1) AU6839196A (en)
DK (1) DK0869809T3 (en)
OA (1) OA10698A (en)
PT (1) PT869809E (en)
RU (1) RU2089179C1 (en)
WO (1) WO1997021443A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251857B1 (en) 1995-12-14 2001-06-26 Novelos Therapeutics, Inc. Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
CN1133611C (en) 1998-01-19 2004-01-07 宝酒造株式会社 Substances capable of inducing appotosis
WO1999050391A1 (en) * 1998-03-30 1999-10-07 I.D.M. Immuno-Designed Molecules Stimulated monocyte derived cells, their preparation and uses
US6251868B1 (en) * 1998-04-30 2001-06-26 Teijin Limited Method for treating a human immunodeficiency virus infection
US6312734B1 (en) * 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US20070142267A1 (en) 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
RU2144374C1 (en) * 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Method of preparing of oxidized glutathione-cis- diaminodichloroplatinum complex and pharmaceutical compositions based on this complex for controlling metabolism, proliferation, and differentiation, and mechanisms of apoptosis of normal and transformated cells
DE10051983A1 (en) * 2000-10-20 2002-06-13 Beate Kehrel Medicaments useful e.g. for preventing thrombosis, inhibiting transplant rejection or treating chronic inflammatory reactions comprises agents inhibiting binding of oxidized proteins to CD36,
AU2002215032A1 (en) * 2000-10-20 2002-04-29 Beate Kehrel Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof
US20030073618A1 (en) * 2001-02-08 2003-04-17 Kozhemyakin Leonid A. Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US20080221029A1 (en) * 2002-10-31 2008-09-11 Regents Of The University Of Colorado Methods for treatment of thiol-containing compound deficient conditions
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
EA010926B1 (en) * 2006-01-20 2008-12-30 Леонид Андреевич Кожемякин Preparation for the treatment of ocular tuberculosis, method for preparation thereof and use
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions
RU2451010C1 (en) * 2011-01-11 2012-05-20 Закрытое Акционерное Общество "Ива Фарм" Palladium-copper catalysts for homogeneous selective oxidation of thiol groups, combination and composition based on said catalysts and therapeutic treatment method
EP2727932B1 (en) * 2011-06-30 2020-05-13 Kaneka Corporation Solid oxidized glutathione salt and method for producing same
RU2659161C1 (en) 2017-11-17 2018-06-28 Общество С Ограниченной Ответственностью "Ива Фарм" Pharmaceutical composition comprising glutathione disulphide and glutathione disulfide s-oxide
CN114425051A (en) * 2022-03-07 2022-05-03 茂名市人民医院 Application of lipoic acid in preparation of medicine for treating sepsis and/or septic shock
CN114617899B (en) * 2022-04-14 2023-10-20 苏州大学附属儿童医院 Application of S-adenosylmethionine in preparation of medicines for treating sepsis-related encephalopathy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1176983B (en) * 1984-10-16 1987-08-26 Zambon Spa DIPEPTIDES WITH PHARMACOLOGICAL ACTIVITY
US4927808A (en) * 1986-07-07 1990-05-22 Teijin Limited γ-L-glutamyl-L-cysteine ethyl ester and pharmaceutical compositions containing the same as an effective ingredient
AU605512B2 (en) * 1986-10-07 1991-01-17 Boehringer Mannheim Italia S.P.A. Pharmaceutical compositions having antineoplastic activity
US4968671A (en) * 1987-11-26 1990-11-06 Yamanouchi Pharmaceutical Co., Ltd. Therapeutic agents for ischemic heart diseases
JPH049336A (en) * 1990-04-26 1992-01-14 Yasuo Komoda Hypnotic agent
US5248697A (en) * 1990-09-20 1993-09-28 Brigham And Women's Hospital Enhancement of glutathione levels with glutamine
DE69220821T2 (en) * 1991-02-04 1997-11-20 Nestle Sa Procedure to ensure adequate tissue intracellular glutathione levels
US5977073A (en) * 1991-06-06 1999-11-02 Life Sciences' Technologies, Inc. Nutrient composition for treatment of immune disorders
US5618823A (en) * 1992-06-24 1997-04-08 Boehringer Mannheim Italia S.P.A. Glutathione as chemoprotective agent
GB9303854D0 (en) * 1993-02-25 1993-04-14 Holt John A G Method for enhancing t-cell count
JPH11507056A (en) * 1995-06-07 1999-06-22 テラピン テクノロジーズ、インク． Metabolic effects of glutathione analogs
US5916878A (en) * 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith

Also Published As

Publication number Publication date
WO1997021443A1 (en) 1997-06-19
US6165979A (en) 2000-12-26
CN1207683A (en) 1999-02-10
OA10698A (en) 2002-11-26
PT869809E (en) 2002-09-30
DK0869809T3 (en) 2002-07-29
CN1161149C (en) 2004-08-11
RU2089179C1 (en) 1997-09-10

Similar Documents

Publication Publication Date Title
AU6839196A (en) Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
AU5793396A (en) Human interferon tau compositions and methods of use
EP0863748A4 (en) Liposomal compositions and methods of using them
AU1692495A (en) Coated abrasives and methods of making same
AU7710198A (en) Single pass lead and method of use
AU6833994A (en) Incorporation of taxol into liposomes and gels
AU4863196A (en) Appetite suppression factor and related methods
AU6268594A (en) Novel silico-titanates and their methods of making and using
AU1023797A (en) Reduction of hair growth
AU5379296A (en) Production of rhein and rhein derivatives
AU5178196A (en) Reduction of hair growth
AU3519893A (en) Antitumor compositions and methods of treatment
AU1532297A (en) Starch-emulsifier composition and methods of making
AU2598195A (en) Fly lines and method of manufacture and use
AU2660095A (en) Combined de-esser and high-frequency enhancer using single pair of level detectors
AU3192389A (en) Novel diazines and their method of preparation
AU4710896A (en) Aluminum alloy composition and methods of manufacture
AU2952192A (en) Highlighting preparation and method of use
AU653064B2 (en) Hydrogel applicator and methods of making same
AU3492997A (en) Soi-transistor circuitry employing soi-transistors and method of manufacture thereof
AU7621496A (en) Microsensor and use of such microsensor
AU7254894A (en) Activated human factor viii and method of preparation
NZ300198A (en) Preparation of n-arylhydroxylamines and n-hetarylhydroxylamines
AU4013495A (en) Chemokine-like proteins and methods of use
AU2453597A (en) Metal casket and method of making the same